Abbott Laboratories v. Alpha Therapeutic Corp.

200 F.R.D. 401, 2001 U.S. Dist. LEXIS 8530, 2001 WL 403186
CourtDistrict Court, N.D. Illinois
DecidedMarch 12, 2001
DocketNo. 97 C 1292
StatusPublished
Cited by28 cases

This text of 200 F.R.D. 401 (Abbott Laboratories v. Alpha Therapeutic Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abbott Laboratories v. Alpha Therapeutic Corp., 200 F.R.D. 401, 2001 U.S. Dist. LEXIS 8530, 2001 WL 403186 (N.D. Ill. 2001).

Opinion

MEMORANDUM AND ORDER

BOBRICK, United States Magistrate Judge.

Before the Court is ABBOTT LABORATORIES’ MOTION TO COMPEL DOCUMENTS RELATING TO INDEMNIFICATION CLAIMS, in which Abbott Laboratories, counter-defendant (“Abbott”) seeks to compel Alpha Therapeutic and Green Cross Corporation (collectively, “Alpha”) to produce any and all documents related to the claims for which Alpha and Green Cross seek indemnification from Abbott, including attorney-client communications and attorney work product.

I. INTRODUCTION

On July 28, 1978, Abbott and Alpha, along with Alpha’s parent corporation, Green Cross, entered into an Asset Acquisition Agreement under which Abbott sold to Alpha certain assets comprising the Abbott Scientific Products Division (“ASPD”). Abbott had previously used the ASPD to manufacture and sell blood products, including products commonly used to treat hemophilia called “factor concentrate.” Under the terms of the Agreement, Abbott transferred certain inventories of blood products including the factor concentrate, the ASPD records, and employees to Alpha.

The Agreement provided that Abbott indemnify Alpha against all claims arising from the use by any person of any inventory obtained by Alpha directly or indirectly from Abbott prior to August 15, 1978, or obtained directly or indirectly by Alpha but owned by Abbott prior to the closing of the contract. That provision of the Agreement (hereinafter, the “Agreement” or “Asset Acquisition Agreement”) also provided that Abbott would not be forced to indemnify Alpha for claims arising out of the use of product transferred from Abbott to the extent that such claims had their origins in Alpha’s own negligence. See, Section 7.01 of Asset Acquisition Agreement.1

The Agreement in § 7.14 also contained a choice of law provision which stipulated that the contract was governed by California law except as to matters required to be governed by the laws of another jurisdiction. Further, the Agreement included a “Cooperation in Connection with Indemnification” provision under which Alpha was obligated to make available to Abbott at all times all business records related to any suit underlying a claim for indemnification from Abbott, and that Alpha would render all reasonably required assistance in order to assure the proper handling of such suits. See, Id. at § 7.02.

A few years subsequent to the transfer of assets between the parties, which included transfer of factor concentrate, hemophiliacs began dying of HIV/AIDS. After a link was drawn between HIV/AIDS infection and use of fractionated blood products, hemophiliacs who had used Alpha's products and contracted the disease began to -sue Alpha. Alpha defended and in many cases settled these claims.

Pursuant to the terms of the Agreement, in 1996 both parties first attempted to negotiate a settlement with respect to indemnification by Abbott for the costs of defending and settling the underlying hemophiliac law suits. When the negotiations broke down Abbott filed a declaratory judgment action with this Court seeking, a determination of the parties respective rights and obligations under the Agreement and specifically, a determination that a settlement had been reached during the negotiations. Alpha answered stating that no such settlement regarding indemnification had been reached and counterclaimed seeking, inter alia, declaratory relief and breach of contract. The [404]*404question of the existence of a binding settlement agreement, resulting from the negotiations between the parties, was resolved by the Seventh Circuit holding that no settlement agreement had been reached. Abbott Laboratories v. Alpha Therapeutic Corp., 164 F.3d 385 (7th Cir.1999). The parties have subsequently continued the indemnification litigation to determine their respective rights and obligations under the Asset Acquisition Agreement and have become embroiled in discovery dispute after discovery dispute, the latest of which is presently before this Court.

In Abbott’s present Motion to Compel Documents Relating to Indemnification Claims, Abbott has asked this Court to order Alpha to produce certain documents that relate “to Alpha’s legal analysis of its actual or potential liability to hemophiliacs infected with viruses carried by Alpha or Green Cross blood factor products.” Abbott’s Motion to Compel, at ¶ 3.2 In its motion Abbott contends that the attorney-client privilege and attorney work product doctrine do not apply to this case and thus Alpha cannot rely on these privileges to shield the documents from disclosure. Abbott also posits as an alternative argument that, should this Court determine that the privileges are applicable, Alpha has waived the privileges by “seeking indemnification from Abbott,.. .by invoking the advice of counsel defense, by its voluntary production of supposedly privileged documents, and having... [Alpha’s] General Counsel Edward Colton testify for two days at a videotaped deposition about the documents that Alpha claims are privileged.” Abbott’s Motion to Compel, at ¶ 3.

Alpha, on the other hand, has argued that the documents at issue are precisely the type of communications that the attorney-client and attorney work product privileges were designed to protect against disclosure. “A hornbook could not provide better examples of protected communications and work-product than those Abbott seeks with its motion.” Alpha’s Response to Abbott’s Motion to Compel, at 2. Alpha also urges that it has in no way waived these privileges with respect to the requested documents.

II. ANALYSIS

A. Applicable Law

Under Federal Rule of Evidence 501, in civil actions or proceedings with respect to an element of a claim or defense as to which State law supplies the rule of decision, the privilege of a witness shall be determined in accordance with State law. Fed.R.Evid. 501. In the instant case, jurisdiction is based on diversity of citizenship. Notwithstanding Alpha’s contention that California law applies to this discovery dispute, pursuant to the governing law provision in the Agreement between the parties, Illinois law supplies the rule of decision regarding the attorney-client privilege. “A district court sitting in diversity applies the law of the state in which it sits regarding privilege.” ConAgra, Inc. v. Arkwright Mutual Ins. Co., 32 F.Supp.2d 1015, 1016 n. 3 (N.D.Ill.1999); CSX Transportation, Inc. v. Lexington Ins. Co., 187 F.R.D. 555, 559 (N.D.Ill.1999); See also, Lorenz v. Valley Forge Ins. Co., 815 F.2d 1095, 1097 (7th Cir.1987). Further, federal courts sitting in diversity cases will apply the choice of law rules emanating from the state in which they sit. See, Klaxon Co. v. Stentor Elec. Mfg., 313 U.S. 487, 496-97, 61 S.Ct. 1020, 85 L.Ed. 1477 (1941).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
200 F.R.D. 401, 2001 U.S. Dist. LEXIS 8530, 2001 WL 403186, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abbott-laboratories-v-alpha-therapeutic-corp-ilnd-2001.